|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-5-29
|
|
pubmed:abstractText |
This study investigated the maximum tolerated dose of S-1 based on the frequency of its dose-limiting toxicities (DLT) with concurrent radiotherapy in patients with locally advanced pancreatic cancer. S-1 was administered orally at escalating doses from 50 to 80 mg m(-2) b.i.d. on the day of irradiation during radiotherapy. Radiation therapy was delivered through four fields as a total dose of 50.4 Gy in 28 fractions over 5.5 weeks, and no prophylactic nodal irradiation was given. Twenty-one patients (50 three; 60 five; 70 six; 80 mg m(-2) seven patients) were enrolled in this trial. At a dose of 70 mg m(-2) S-1, two of six patients demonstrated DLT involving grade 3 nausea and vomiting and grade 3 haemorrhagic gastritis, whereas no patients at doses other than 70 mg m(-2) demonstrated any sign of DLT. Among the 21 enrolled patients, four (19.0%) showed a partial response. The median progression-free survival time and median survival time for the patients overall were 8.9 and 11.0 months, respectively. The recommended dose of S-1 therapy with concurrent radiotherapy is 80 mg m(-2) day(-1). A multi-institutional phase II trial of this regimen in patients with locally advanced pancreatic cancer is now underway.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-10473078,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-10901361,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-11013279,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-11592762,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-11681245,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-11955742,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-12826246,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-14665608,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-14758134,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-15172641,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-15226765,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-15361643,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-16002845,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-16006754,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-16446337,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-16505434,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-16865244,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-17094397,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-2898536,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-7284971,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-8653704,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-8862723,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-9118032,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17533388-9893658
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
4
|
|
pubmed:volume |
96
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1650-5
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17533388-Aged,
pubmed-meshheading:17533388-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17533388-Carcinoma,
pubmed-meshheading:17533388-Combined Modality Therapy,
pubmed-meshheading:17533388-Dose-Response Relationship, Drug,
pubmed-meshheading:17533388-Drug Combinations,
pubmed-meshheading:17533388-Female,
pubmed-meshheading:17533388-Humans,
pubmed-meshheading:17533388-Male,
pubmed-meshheading:17533388-Maximum Tolerated Dose,
pubmed-meshheading:17533388-Middle Aged,
pubmed-meshheading:17533388-Oxonic Acid,
pubmed-meshheading:17533388-Pancreatic Neoplasms,
pubmed-meshheading:17533388-Survival Analysis,
pubmed-meshheading:17533388-Tegafur,
pubmed-meshheading:17533388-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
|
|
pubmed:affiliation |
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan. masikeda@ncc.go.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I
|
